Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

Journal Articles

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

Qi Zhang, PhD, Lina Han, PhD, Alessia Lodi, PhD, Connie Weng, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Helen Ma, MS, Abhishek Maiti, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142547

Published: 2020

Journal Articles

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Anudishi Tyagi, PhD, Bin Yuan, Stanley Ly, Fouad El-Dana, MD, Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Christine B Peterson, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Behrang Amini, MD PhD, Venkata Lokesh Battula, PhD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-142777

Published: 2020

Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-134924

Published: 2020

Journal Articles

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Kenneth H. Shain, MD PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Constantine Logothetis, MD, Christian Argueta, PhD, Yosef Landesman, PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140485

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria Silva, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan R Alugubelli, MS, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142872

Published: 2020

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 738.

https://doi.org/10.1182/blood-2019-128909

Published: 2019

Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MDMSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2637.

https://doi.org/10.1182/blood-2019-127803

Published: 2019

Journal Articles

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 645.

https://doi.org/10.1182/blood-2019-128547

Published: 2019

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Lina Han, PhD, Antonio Cavazos, Natalia Baran, PhDMD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Joseph R Marszalek, PhD, Michael Andreeff, MD PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 5161.

https://doi.org/10.1182/blood-2019-124475

Published: 2019

Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1267.

https://doi.org/10.1182/blood-2019-125725

Published: 2019

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1375.

https://doi.org/10.1182/blood-2019-124963

Published: 2019

Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1369.

https://doi.org/10.1182/blood-2019-128618

Published: 2019

Journal Articles

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 286.

https://doi.org/10.1182/blood-2018-99-113749

Published: 2018

Journal Articles

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Seemana Bhattacharya, PhD, Sujan Piya, PhD, Qi Zhang, PhD, Natalia Baran, PhD MD, Teresa McQueen, MS, R. Eric Davis, MD, Nicholas Cosford, PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 3934.

https://doi.org/10.1182/blood-2018-99-114817

Published: 2018

NARROW

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only